Selinexor for rhabdoid tumor

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 1 Aug 2023: Trial started, NCT05985161
  2. 14 Aug 2023: Trial registered, NCT05985161

The trials

NCT05985161: A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors

State
Under way
Phase
Phase 2
People
45 planned
Started
1 Aug 2023
Primary completion
1 Aug 2029
Arms
Cohort A.1 Wilms Tumor, Cohort B.1 Rhabdoid Tumor, Cohort C.1 MPNST, Cohort D.1 Other Solid Tumor, Cohort E.1g BCOR driven sarcoma
Results
None posted
  1. 1 Aug 2023: Trial started
  2. 14 Aug 2023: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Also known as Xpovio.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.